- Zimmer Biomet came in a little light for the fourth quarter, as the pandemic led to an unexpected slowdown in elective procedures late in the quarter.
- Sustained share gains from Stryker will remain challenging, but the expansion of Rosa placements and the new Persona IQ will help grow the business.
- Splitting off the Spine and Dental business will create a faster-growing, more profitable Zimmer, but the combo is not a natural one and both businesses have been under-supported by Zimmer.
- Zimmer shares offer okay return prospects today, but better execution can drive a stronger share price.
For further details see:
Zimmer Biomet Sees Some Pandemic-Related Turbulence, But Continues Its Self-Improvement Drive